Loading…
Loading…
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously. The revised timing reflects the event-driven nature of the study. PACIFIC-9 is an AstraZeneca-led Phase 3 trial evaluating durvalumab in combination with monalizumab or oleclum.
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Innate Pharma (IPHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ: IPHA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The
Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript